Loading...
Loading...
TRVI| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 35.0K |
| Gross Profit | -35.0K |
| Operating Expense | 9,045.0K |
| Operating I/L | -9,045.0K |
| Other Income/Expense | 1,334.0K |
| Interest Income | 1,183.0K |
| Pretax | -7,711.0K |
| Income Tax Expense | -13.0K |
| Net Income/Loss | -7,698.0K |
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently in phase IIb/III clinical trials for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis. The company generates revenue through the development and commercialization of Haduvio, with a license agreement in place with Endo Pharmaceuticals Inc. to develop and market products containing nalbuphine hydrochloride in any formulation.
